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Introduction
While many organs not classified as endocrine glands, e.g., fat,
are now known to produce hormones, cytokines, and other
chemical messengers and secrete them directly into the blood-
stream, the pituitary, thyroid, parathyroids, pancreatic islets,
adrenals, testes, and ovaries, i.e., the “classical” endocrine
glands (Figure 1), are the focus of this review. As with other tis-
sues and organs, endocrine neoplasia may be benign or malig-
nant, and may occur on a sporadic or hereditary basis. Sporadic
forms of benign endocrine neoplasia involving the classic
endocrine glands, and sporadic endocrine malignancies, of
which thyroid cancers are the most common (see Segev et al.,
2003, for recent review), and others such as adrenocortical can-
cer, much rarer (see Sidhu et al., 2004, for review), are beyond
the scope of this review. The focus of this article is on seven
endocrine neoplasia syndromes which often involve multiple
endocrine glands, with or without prominent involvement of
nonendocrine organs (Table 1). There are additional hereditary
tumor predisposition syndromes whose phenotype may include
endocrine neoplasia: gonadal tumors in Peutz-Jeghers syn-
drome caused by LKB1 mutations, adrenocortical cancer in Li-
Fraumeni syndrome caused by TP53 mutations, islet cell
tumors in tuberous sclerosis caused by TSC1 and 2 mutations,
follicular thyroid cancer in Cowden syndrome caused by PTEN
mutations, papillary thyroid tumors in familial adenomatous
polyposis caused by APC mutations, and pheochromocytomas
in neurofibromatosis caused by NF1 mutations. These have
been reviewed recently (Nagy et al., 2004) and will not be dis-
cussed further here.
Recent advances in understanding the molecular patho-
genesis of endocrine neoplasia syndromes have ushered in a
new era of diagnosis, and in some cases new forms of treat-
ment and prevention. Despite the rareness of these endocrine
neoplasia syndromes, insights gained from understanding their
molecular pathogenesis should lead to improvements in man-
agement of both hereditary and sporadic endocrine and nonen-
docrine neoplasms. Following a general discussion of the
genetics, clinical manifestations, and management of these
syndromes, I will highlight specific features, including molecular
pathogenesis, of each.
Genetics
Hereditary endocrine neoplasia syndromes were first recog-
nized based on a common pattern of endocrine (and nonen-
docrine) manifestations inherited in a Mendelian manner,
typically autosomal dominant. Recognition that these disorders
were caused by single gene mutations led to efforts to identify
such genes by linkage and positional cloning. Most hereditary
tumor predisposition syndromes are caused by germline loss-
of-function mutations of a single allele; frequent somatic loss of
the wild-type allele leads to clonal neoplasms, and accounts for
the high penetrance of the tumor phenotype, as well as appar-
ent autosomal dominant inheritance (Vogelstein and Kinzler,
2004; Nagy et al., 2004). Germline mutations in such tumor sup-
pressor genes (TSG) are the cause of five of the seven
endocrine neoplasia syndromes, including multiple endocrine
neoplasia type 1 (MEN1), Carney complex (CC), von Hippel-
Lindau disease (VHL), hyperparathyroidism-jaw tumor syn-
drome (HPT-JT), and hereditary paranganglioma syndrome
(PGL). For CC and HPT-JT, the evidence for loss of the wild-
type allele in tumors is not definitive (Bossis et al., 2004;
Carpten et al., 2002), and it remains possible for these and
other TSG that loss of a single allele, because of haploinsuffi-
ciency, confers a selective growth advantage. Multiple
endocrine neoplasia type 2 (MEN2) is exceptional in being
caused by a germline-activating mutation of the RET oncogene,
a receptor-tyrosine kinase (Gertner and Kebebew, 2004). In
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Figure 1. Major sites developing benign and/or malignant tumors in
endocrine neoplasia syndromes
Multiple endocrine neoplasia types 1 and 2 (MEN1 and MEN2, respective-
ly), McCune-Albright syndrome (MAS), Carney complex (CNC), hyper-
parathyroidism-jaw tumor syndrome (HPT-JT), hereditary paranganglioma
syndrome (PGL), and von Hippel-Lindau disease (VHL).
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general, germline-activating mutations of oncogenes are
embryonic lethal, as are homozygous, inactivating mutations of
TSG. The restricted range of expression of the RET oncogene
may explain why germline-activating mutations of this gene are
not embryonic lethal. The McCune-Albright syndrome (MAS) is
included in this review because of its pleiotropic endocrine and
nonendocrine phenotype, but it is not a hereditary syndrome. It
is caused by somatic activating mutations of GNAS, encoding
Gsα, the ubiquitously expressed G protein, coupling many
receptors to stimulation of cAMP formation. In some respects,
constitutively activated Gsα behaves like an oncogene, and
germline activating mutations would likely be embryonic lethal.
MAS, however, results from early postzygotic GNAS mutations
that occur in a mosaic distribution (Spiegel and Weinstein,
2004).
General clinical features and management of hereditary
endocrine neoplasia syndromes
Features unique to hereditary endocrine neoplasia syndromes
include multiplicity of tumors for a given endocrine organ, e.g.,
multiple parathyroid tumors in MEN1, MEN2, and HPT-JT, bilat-
eral adrenal cortical tumors in CC, bilateral adrenal medullary
tumors in MEN2, and multiple enteropancreatic tumors in
MEN1, as well as multiplicity of endocrine organs developing
tumors, e.g., MEN1 and MEN2 by definition, but also CC, VHL,
PGL, and MAS. This reflects the consequences of mutation of
TSG/oncogenes expressed in every cell of the susceptible tis-
sue, and contrasts with the single endocrine tumor pattern seen
in typical sporadic cases caused by somatic mutation in a single
cell. A related difference is that the age of onset of tumors is typ-
ically significantly younger in hereditary compared with sporadic
cases. Since surgical removal is the primary mode of treatment
for most endocrine tumors, this difference in tumor multiplicity is
critical in management. Removal of a single tumor is generally
not curative because of the high likelihood of residual or recur-
rent tumor.
An important, largely unresolved question is the basis for
the specific phenotypes associated with mutations of the genes
responsible for these endocrine neoplasia syndromes. In
MEN2, the involvement of neural crest-derived tissues such as
the C cells of the thyroid and the adrenal medulla reflects the
somewhat restricted range of expression of the RET oncogene.
But in MEN1, for example, it is not at all clear why loss of func-
tion of this ubiquitously expressed gene should lead to a rela-
tively unique pattern of endocrine and nonendocrine neoplasia
(Table 1). Possible explanations include tissue-specific differ-
ences in somatic loss of the wild-type allele, in availability of
alternative growth regulatory pathways, and in expression of
key proteins interacting with TSG products. A related question
concerns the extent of correlation between genotype and phe-
notype. In MEN2, VHL, and PGL, unique phenotypic patterns
are associated with specific gene mutations (see later sec-
tions), but for MEN1, CC, and HPT-JT, such correlations either
do not exist or are not yet apparent. There is substantial varia-
tion in penetrance and in pattern of tumor formation in these
syndromes both between different families and even within fam-
ilies, suggesting that other modifying genes and/or environmen-
tal factors may play a role.
The clinical manifestations of the endocrine tumors associ-
ated with these syndromes often reflect the biochemical conse-
quences of excess hormone secretion, e.g., hypercalcemia due
to hyperparathyroidism and hypoglycemia due to hyperinsuline-
mia. Increased hormone secretion also serves as a tumor mark-
er, e.g., calcitonin secretion in medullary thyroid carcinoma
(MTC). Tumor mass effects, however, from both benign (e.g.,
pituitary adenoma encroachment on the optic chiasm) and
malignant (e.g., metastatic disease associated with MTC and
parathyroid and pancreatic islet carcinomas) endocrine tumors
may also dominate the clinical picture.
All of the clinical features discussed above have important
implications for patient management. Biochemical measures of
endocrine function and noninvasive imaging methods were pre-
viously the mainstays of family screening, but identification of
the genes responsible for these syndromes provides the oppor-
tunity for genetic, including prenatal, diagnosis (see Shapiro et
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Table 1. Endocrine neoplasia syndromes
Syndrome Gene/ Subcellular Biochemical Pathway Tissue Endocrine Nonendocrine 
protein localization function expression manifestations manifestations
MEN1 MEN1/ Nuclear ? ? Ubiquitous Anterior pituitary, Facial angiofibromas, 
MENIN parathyroid, collagenoma, lipomas, 
enteropancreatic leiomyomata
HPT-JT HRPT2/ Nuclear ? ? Ubiquitous Parathyroid cystic Ossifying jaw fibroma, 
PARAFIBRO- tumor/carcinoma renal cyst, Wilms tumor
MIN
McCune- GNAS/Gsα Plasma 7TM receptor cAMP Ubiquitous Anterior pituitary, adrenal Fibrous dysplasia of bone, 
Albright membrane coupling signaling cortex, gonads, thyroid café-au-lait skin pigmentation
Carney PRKAR1A/ Cytoplasmic PKA cAMP- cAMP Ubiquitous Anterior pituitary, adrenal Skin lentigines, myxomas
complex PKA RIα binding subunit signaling cortex, gonads, thyroid
PGL SDHB/C/D Mitochondrial Succinate Krebs cycle/ Ubiquitous Head/neck Renal cell CA? (SDHB only)
to fumarate electron paraganglioma, 
transport pheochromocytoma, 
chain thyroid CA? (SDHB)
von VHL Cytoplasmic Ubiqutin ligase O2-sensing Ubiquitous Pancreatic islet, Renal cell CA, 
Hippel- complex pheochromocytoma hemangioblastomas
Lindau
MEN2 RET Plasma Tyrosine kinase Growth factor Neural crest- Medullary CA of thyroid, Hirschsprung disease (2A only), 
membrane signaling derived pheochromocytoma, ganglioneuromas (2B only)
parathyroid (2A only)
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al., 2003, for listing of CLIA-certified labs) and genetic counsel-
ing for at-risk family members. When the family history is posi-
tive or suggestive, the need to screen for mutation is evident,
but individuals with phenotypic features of a hereditary
endocrine neoplasia syndrome lacking a positive family history
may also deserve mutation screening, since identification of de
novo germline mutations has important implications for coun-
seling and screening of offspring. Prospective management of
family members in whom disease-causing mutations have been
identified poses numerous challenges. Measurement of hor-
mone secretion and imaging studies remain important, and in
selected cases (see discussion of MEN2), prophylactic surgical
removal of endocrine glands is appropriate. There are excellent
surgical or pharmacologic treatments for excessive hormone
secretion in these syndromes, but with the exception of C cell
neoplasia in the thyroid, the endocrine cancers are difficult to
prevent or cure.
Multiple endocrine neoplasia type 1 (MEN1)
Hyperparathyroidism is the most frequent (nearly 100% pene-
trance) and generally earliest manifestation of MEN1. Anterior
pituitary tumors, most commonly prolactinomas, occur in ?30%
of cases, and enteropancreatic tumors in 30%–80% (Nagy et
al., 2004). MEN1 is defined as occurrence of 2 of these 3 fea-
tures, and familial MEN1 as an MEN1 case having at least one
first-degree relative with one tumor. The overall incidence is
estimated at 1–2/100,000. Other less striking features include
adrenal cortical and medullary tumors, thymic and foregut carci-
noids, lipomas, facial angiofibromas, collagenomas, and
leiomyomas. Zollinger-Ellison syndrome, caused by duodenal
gastrinomas, was formerly the major cause of mortality, but with
more effective treatment with proton pump inhibitors, malignant
enteropancreatic tumors and thymic carcinoids are now the
major cause of mortality. Since enteropancreatic tumors are
multifocal and difficult to remove completely, and not all are
functional, there is no consensus on surgical management.
Thymic carcinoids, especially in males, may be malignant;
hence, prophylactic transcervical thymectomy is advised at the
time of initial parathyroidectomy. Indications for genetic testing
include confirmation of diagnosis in atypical cases, e.g., MEN1
tumors without family history, but the role of testing in at-risk rel-
atives is unclear, because of the lack of consensus regarding
the role of prophylactic surgery.
The MEN1 gene encodes MENIN, a highly conserved
nuclear protein that is not a member of any known gene family
and which lacks identified functional domains (Agarwal et al.,
2004). Multiple menin-interacting proteins, such as junD and the
MLL histone methyltransferase complex, have been reported,
but as yet, the role of any in tumorigenesis is unproven. Several
hundred germline loss-of-function mutations have been identi-
fied, and loss of the wild-type allele in MEN1 tumors supports a
tumor suppressor gene function.There is no evidence for genet-
ic heterogeneity, but because mutations are widely dispersed
throughout the gene, only ?75% of MEN1 cases have had
mutations identified. Although unique phenotypic variants exist,
e.g., high prolactinoma occurrence, no clear genotype/pheno-
type correlations have emerged. Somatic mutations have been
identified in 20%–30% of sporadic parathyroid and islet tumors.
Familial isolated hyperparathyroidism (FIHP) has been con-
sidered a possible forme fruste of MEN1 (cf. familial MTC in
MEN2), but MEN1 mutations have been identified in only a
minority of cases. Mutations of the hyperparathyroidism-jaw
tumor syndrome gene (see below) are also a rare cause of
FIHP (Simonds et al., 2004), as are calcium-sensing receptor
gene mutations. Mutation of a distinct gene as the cause of
most cases of FIHP, as is evidently the case for familial soma-
totroph tumors linked to 11q13 (Luccio-Camelo et al., 2004),
remains a possibility.
Hyperparathyroidism-jaw tumor syndrome (HPT-JT)
Hyperparathyroidism caused by multiple, often cystic, and
occasionally malignant parathyroid tumors is the defining and
most common feature of HPT-JT. Ossifying fibromas of the
mandible or maxilla occur in up to 30% of cases, as do renal
cysts; more rarely, Wilm’s tumor, Hurthle cell thyroid adenomas,
pancreatic adenocarcinoma, and testicular germ cell tumors
are seen (Thakker, 2004). HPT-JT is caused by germline 
loss-of-function mutations in a gene, HPRT2, encoding a 
protein termed PARAFIBROMIN (Carpten et al., 2002).
PARAFIBROMIN is highly conserved in most species and
shows homology to the yeast cdc73p gene that encodes an
accessory protein of the RNA polymerase II complex. Recent
evidence suggests that human PARAFIBROMIN occurs in the
nuclear paf complex in association with RNA polymerase II, but
its specific biochemical function, and how its loss leads to
tumorigenesis, remain to be defined (Agarwal et al., 2004).
HPRT2 somatic mutations have been identified in sporadic cys-
tic parathyroid tumors (Carpten et al., 2002). HPRT2 mutations
were also identified in 10/15 cases of sporadic parathyroid car-
cinoma, with three of the mutations found in the germline in one
study (Shattuck et al., 2003), and somatic mutations in four of
four sporadic parathyroid carcinomas in another (Howell et al.,
2003).These results emphasize the importance of genetic diag-
nosis even in apparently sporadic parathyroid carcinoma, and
the need for imaging for possible jaw and renal lesions. Genetic
screening of family members offers the possibility of defining
those at-risk who require careful monitoring with serum calci-
um. Although prophylactic parathyroidectomy is a theoretical
option, potential complications and insufficient data regarding
likelihood of metastatic parathyroid cancer in specific cases
restrain this approach. Early en bloc resection of parathyroid
cancer is the only current curative procedure, but novel
approaches such as immunotherapy using parathyroid hor-
mone as antigen may lead to both reversal of hypercalcemia
and regression of lung metastases (Betea et al., 2004).
McCune-Albright syndrome (MAS)
MAS is classically defined by the triad of polyostotic fibrous dys-
plasia, café-au-lait skin lesions, and gonadotropin-independent
sexual precocity, although these patients may also develop
tumors (or nodular hyperplasia) of pituitary somatotrophs, thy-
roid, or adrenal cortex with associated hormonal oversecretion,
and other nonendocrine abnormalities (e.g., cardiomyopathy,
sudden death, liver abnormalities, and intramuscular myxo-
mas). Activating GNAS mutations encode substitutions of either
Arg201 or Gln227, and lead to constitutive, agonist-independent
cAMP stimulation by disrupting the intrinsic GTPase activity that
normally terminates G protein activation (Spiegel and
Weinstein, 2004). It is believed that the somatic mutation in
MAS patients occurs early in development, and therefore the
clinical spectrum in each individual is determined by the tissue
distribution of mutant-bearing cells. Somatic, activating GNAS
mutations may also occur later in development, causing more
focal forms of fibrous dysplasia, pituitary somatotroph, and thy-
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roid tumors. Sporadic and inherited forms of thyroid and testicu-
lar Leydig cell neoplasia may also be caused by somatic and
germline mutations, respectively, of the Gs-coupled thyrotropin
and luteinizing hormone receptors (Spiegel and Weinstein,
2004). The common pathogenetic mechanism in each of these
disorders is the ability of constitutive cAMP activation to stimu-
late cell proliferation in endocrine and some nonendocrine tis-
sues. Because regulation of hormone secretion and cell
proliferation are linked in endocrine tissue (cf. hyperplasia sec-
ondary to demand for increased hormone secretion), a primary
defect in regulation of hormone secretion such as Gsα mutation
can cause benign, if not malignant, neoplasia (Marx, 1999). A
similar mechanism, but involving a different G protein pathway,
is involved in parathyroid neoplasia in neonatal severe primary
hyperparathyroidism caused by loss of function of both alleles
of the calcium-sensing receptor.
Carney complex (CNC)
CNC is a rare disorder (?400 cases in the NIH/Mayo registry)
with pleiotropic endocrine and nonendocrine manifestations
(Bossis et al., 2004). Primary pigmented nodular adrenocortical
disease is the most common endocrine manifestation, occur-
ring in ?25% of affected cases. Cortisol hypersecretion may
range from the classic picture of Cushing’s disease to an insidi-
ous or cyclical form manifesting first with osteoporosis, myopa-
thy, or cachexia. Pituitary, thyroid (rarely malignant), and
testicular Sertoli cell tumors and ovarian cysts also occur.
Nonendocrine features include early appearance of pigmented
skin lesions, cardiac myxomas, and schwannomas. Surgical
removal of hormone-hypersecreting tumors and of cardiac myx-
omas is the usual treatment, but appropriate management
depends on recognition of the disorder.
Genetic diagnosis is now feasible with the discovery that
germline loss-of-function mutations in the PRKAR1A gene with-
in the 17q-linked locus are responsible for one form of the dis-
ease. A gene in another linked locus, 2p16, has yet to be
identified. The PRKAR1A gene encodes one of the four regula-
tory subunits of cAMP-dependent protein kinase (PKA). Given
the complexity in forms of PKA, a heterodimer composed of
potentially multiple forms of regulatory and catalytic subunits,
the biologic consequences of loss of this particular gene are not
straightforward, but biochemical assays suggest a net increase
in PKA activity following cAMP stimulation. In certain cell types
(see MAS above), increased cAMP signaling is mitogenic and
may account for the pleiotropic manifestations. Somatic muta-
tions in the PRKAR1A gene in some sporadic adrenocortical
and thyroid tumors further underscore the pathogenic impor-
tance of this pathway. As with MAS, inhibition of the cAMP path-
way might provide a novel, targeted therapy.
Hereditary paraganglioma syndrome (PGL)
Tumors of the autonomic nervous system have been divided
into head and neck paragangliomas (typically nonfunctioning)
and adrenal medullary and extra-adrenal catecholamine-
secreting pheochromocytomas (PC).Their estimated total year-
ly incidence is 1/300,000 (Neumann et al., 2004). Hereditary PC
occur in PGL, VHL, MEN2, and NF1. In PGL, affected subjects
typically have multiple head/neck paragangliomas and/or PC,
with the latter manifesting clinically with paroxysmal hyperten-
sion and catecholamine hypersecretion. Tumor removal with
adrenal cortical-sparing laparascopic surgery for PC is the main
treatment. Despite the potential multiplicity of tumors, the mor-
bidity of total adrenalectomy argues against prophylactic
removal of both adrenals for PGL, as well as VHL and MEN2.
Four forms of PGL (1–4) are recognized; the gene responsi-
ble for PGL2 remains unidentified, but PGL1, 3, and 4 are
caused by germline loss-of-function mutations in 3 of the 4 sub-
units of the succinate dehydrogenase (SDH) complex II of the
mitochondrial electron transport chain, SDHD, SDHC, and
SDHB, respectively (Eng et al., 2003). Only 4 families with
SDHC mutations have been reported, but 10% of index patients
in a large European registry of PC/paraganglioma had
SDHB/SDHD germline mutations. Also, 25% of apparently spo-
radic, symptomatic PC subjects turn out to have germline muta-
tions in SDHB, SDHD, VHL, or RET genes. Among the
genotype/phenotype correlations described are a greater inci-
dence of PC and paraganglioma in SDHD versus SDHB muta-
tion-bearing subjects, when the maternal imprinting of the
SDHD gene is taken into account, i.e., individuals inheriting
SDHD mutations from their mother do not show tumors since
the maternal allele is not expressed. SDHB mutations, however,
are associated with a greater risk of malignant PC and with
occurrence of renal and thyroid cancers. These correlations
point to a strategy for prioritizing which gene to sequence first in
subjects with different clinical presentations. Genetic diagnosis
allows screening and prospective monitoring of at-risk family
members with imaging and catecholamine measurements. How
loss of SDH activity causes tumorigenesis, the basis for tissue-
specific tumorigenesis, and the basis for the varying clinical
expressions of mutations in different SDH subunits remain
unclear, but speculations focus on possible effects on apoptosis
pathways and on angiogenesis due to free radical formation
(Eng et al., 2003).
von Hippel-Lindau disease (VHL)
VHL has an estimated birth incidence of 1/36,000/year and a
penetrance of 95%–100% by age 65 (Nagy et al., 2004). PC in
up to 20% of cases is the major endocrine manifestation, but
islet cell tumors also occur. Retinal and cerebellar heman-
gioblastomas and renal cell cancer (all in up to 60% of cases)
are the main nonendocrine features. Imaging for diagnosis and
surgical treatment can be applied in a more targeted manner
based on identification of loss-of-function mutations in the VHL
gene as the cause of the disease, and the relatively specific
phenotypes associated with particular VHL mutations (Clifford
et al., 2001). The VHL gene encodes a subunit of a ubiquitin lig-
ase complex that regulates degradation of the hypoxia-inducible
transcription factor (HIF1). Type 1 disease, in which heman-
gioblastoma and renal cell cancer but not PC are common, is
associated with truncation, deletion, and protein-folding muta-
tions that impair regulation of HIF1. Resultant upregulation of
assorted proangiogenic genes is thought to account for the
associated tumors. Type 2 disease, in which PC is common, is
associated with various missense mutations, and is further sub-
divided into 2A (renal cell cancer rare), 2B (renal cell cancer
also), and 2C (PC only). In type 2C, mutated VHL protein may
still downregulate HIF1, but abnormal extracellular matrix for-
mation may account in ways yet unexplained for PC formation
(Hoffman et al., 2001). Loss of VHL function has also been
described in sporadic hemangioblastoma and renal cell cancer,
but not PC. These interesting but still incompletely understood
associations point to potential utility of angiogenesis inhibitors
for at least some forms of VHL. The VHL gene pathway, its role
in tumorigenesis, and opportunities for disease-specific
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approaches to therapy are covered in an excellent recent review
on kidney cancer (Linehan and Zbar, 2004).
Multiple endocrine neoplasia type 2 (MEN2)
Between 500–1000 kindreds with MEN2 have been reported.
The incidence of its major component, MTC, is 1/million/year,
with 25%–50% of cases being hereditary (Gertner and
Kebebew, 2004). MEN2 is caused by germline activating muta-
tions of RET, which encodes a transmembrane tyrosine kinase
that binds members of the glial-derived neurotrophic factor
(GDNF) family by associating with coreceptors for GDNF. As
with other receptor-tyrposine kinases, agonist binding promotes
receptor dimerization, transphosphorylation of key intracellular
tyrosines, binding of intracellular adaptor proteins to phospho-
rylated tyrosines, and thereby stimulation of ras/mitogen acti-
vated protein kinase and PI3 kinase/AKT cascades.
The limited number of disease-causing missense mutations
facilitates genetic diagnosis, and is associated with distinct phe-
notypes.Type 2A mutations most often involve extracellular cys-
teines, preventing intramolecular disulfide formation and
leading instead to intermolecular disulfide formation, receptor
dimerization, and constitutive activation. Mutations in cysteines
at codons 609–620 may cause familial MTC only. Mutation of
cysteine 634 is the most frequent cause of MEN2A: MTC asso-
ciated with PC (50%) and hyperparathyroidism (15%–30%).
Rarely, MEN2A may occur in association with Hirschsprung dis-
ease (loss of enteric ganglia). The latter is typically associated
with germline loss-of-function mutations of RET. Codon
609–620 missense mutations simultaneously reduce cell sur-
face expression while causing constitutive activation of those
receptors that do reach the cell surface.The presumption is that
development of enteric ganglia is more sensitive to reduced
RET expression than thyroid C cells, explaining the combination
of MTC due to constitutive RET activation and Hirschsprung
disease due to RET loss of function. M918T is the most frequent
type 2B mutation, and involves a conserved catalytic core
residue that changes substrate specificity. How altered RET
specificity leads to the Type 2B phenotype, with MTC, PC,
mucosal, and intestinal neuromas, and a marfanoid habitus, is
not clear, but MEN2B tumors have a different gene expression
pattern than do MEN2A tumors (Santoro et al., 2004). Germline
RET mutations may also be found in apparently sporadic MTC
and/or PC.
Before RET gene discovery, prospective screening of at-
risk family members involved calcitonin stimulation testing.
Although this allowed identification of C cell hyperplasia as a
pre-MTC lesion, it was insufficiently sensitive to identify muta-
tion carriers early enough to prevent metastatic MTC in all.
Studies using genetic diagnosis have documented the benefit
of prophylactic thyroidectomy, notwithstanding risks of recurrent
laryngeal nerve damage and hypoparathyroidism, in asympto-
matic carrier children (Machens et al., 2003). Guidelines for
management of MEN2 provide a paradigm for eventual man-
agement of other genetic forms of cancer (Cote and Gagel,
2003). Since MTC is relatively resistant to conventional forms of
chemo- or radiation therapy, newer targeted therapies based on
understanding of RET signaling are being tested (Santoro et al.,
2004).
Future challenges
Although there has been dramatic progress in identifying the
genetic basis for endocrine neoplasia syndromes, the challenge
now is to translate this progress into more effective ways to treat
and prevent these diseases. To do so will require defining the
fundamental biologic roles for tumor suppressor gene products
such as MENIN and PARAFIBROMIN, and the precise mecha-
nisms responsible for tumorigenesis in all of the endocrine neo-
plasia syndromes. Only with a deeper understanding of such
mechanisms can we hope to explain the basis for the unique
phenotypic features of these diseases, such as tissue-specific
tumor formation patterns. More robust methods for mutation
identification and a clearer understanding of possible genotype-
phenotype correlations are of obvious importance with regard to
family screening and genetic counseling. Because conventional
chemotherapy and radiotherapy are generally poorly effective in
malignant forms of endocrine neoplasia, early genetic diagno-
sis and prevention are desirable goals. Prophylactic surgery,
however, may only be warranted for endocrine glands such as
the thyroid that can be removed relatively safely early in life, and
for which there is adequate lifelong hormone replacement. That
is one major reason why development of targeted therapies
capable of safely and effectively blocking the specific pathways
leading to endocrine neoplasia will be a high priority for future
research.
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